Prostate cancer (PCa) incidence and mortality have rapidly increased in China. Notably,
unique epidemiological characteristics of PCa are found in the Chinese PCa population …

The oligometastatic state has been proposed as an intermediate stage of cancer spread
between localized disease and widespread metastases. With improvements in diagnostic …

Purpose Docetaxel added to androgen-deprivation therapy (ADT) significantly increases the
longevity of some patients with metastatic hormone-sensitive prostate cancer. Herein, we …

Background The cornerstone of standard treatment for patients with primary bone metastatic
prostate cancer (mPCa) is androgen deprivation therapy (ADT). Retrospective studies …

Purpose There is growing interest in the role of local therapies, including external beam
radiotherapy (RT), for men with metastatic prostate cancer (mPCa). We used the National …

Background The role of local treatment (LT) in patients with metastatic prostate cancer
(mPCa) at diagnosis is controversial. Objective We set to evaluate the potential impact of LT …

Background Treatment of the primary, termed local therapy (LT), may improve survival in
metastatic prostate cancer (mPCa) versus no local therapy (NLT). Objective To assess …

The possible treatments options for metastatic hormone-sensitive prostate cancer (mHSPC)
have dramatically increased during the last years. The old backbone, which androgen …

Context The current standard of care for metastatic prostate cancer (PCa) is androgen
deprivation therapy (ADT) plus either docetaxel or abiraterone. Growing evidence suggests …

Background Previous studies suggested that men with metastatic prostate cancer might
benefit from local treatment of the primary tumor. Objective To determine whether radical …